BPC-157

BPC-157 exerts its biological effects through multiple interconnected pathways. At the molecular level, it modulates the nitric oxide (NO) system, promoting vasodilation and angiogenesis — the formation of new blood vessels — in injured tissue. This enhanced blood supply is critical for delivering oxygen and nutrients to damaged areas, accelerating the healing process.

The peptide also interacts with the FAK-paxillin signalling pathway, which governs cell migration, adhesion, and proliferation. By upregulating growth factors such as EGF, VEGF, and FGF, BPC-157 stimulates fibroblast activity and collagen deposition, essential processes in tendon, ligament, and muscle repair.

Additionally, BPC-157 has demonstrated cytoprotective properties in the gastrointestinal tract, protecting mucosal integrity against damage from NSAIDs, alcohol, and stress-induced lesions. Its interaction with the dopaminergic and serotonergic systems also points to neuroprotective and mood-modulating potential, making it one of the most versatile peptides under active investigation.

BPC-157 was first isolated from human gastric juice in the early 1990s by a research team at the University of Zagreb, led by Professor Predrag Sikiric. The discovery that a stable gastric peptide fragment could accelerate wound healing across multiple tissue types attracted significant scientific interest.

Since its initial characterisation, BPC-157 has been the subject of over 100 peer-reviewed studies, primarily in animal models. These studies have investigated its effects on tendon healing, gastrointestinal protection, neurological recovery, and even bone fracture repair. While human clinical trials remain limited, the breadth and consistency of preclinical data have made BPC-157 one of the most widely researched peptides in regenerative medicine.